Several clinical trials are currently active (NCT02073994, NCT02989857, NCT02074839, NCT04195555) to evaluate AG-120 (IDH-mutant inhibitor) efficacy and safety in several cancer types, being this already FDA-approved for IDH-mutant relapsed or refractory acute myeloid leukemia (218, 219). Here, IDH2 is linked to cancer.